Upadacitinib Impurity 17--(3R,4S)-benzyl 3-(2-((ethoxycarbonyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)amino)acetyl)-4-ethylpyrrolidine-1-carboxylate
2050038-81-6
Pharmaceutical Grade
90%
Shanghai Port or Shenzhen Port
H&D
A temperature-controlled box with a capacity of up to 10g
2025-01-26
Drug impurity reference,Impurity reference,Reference substance,impurity
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
Benzyl (3R,4S)-3-(N-(ethoxycarbonyl)-N-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)glycyl)-4-ethylpyrrolidine-1-carboxylate
Other Name:2050038-81-6;SCHEMBL18767291;AMY25492;(3R,4S)-Benzyl 3-(2-((ethoxycarbonyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)amino)acetyl)-4-ethylpyrrolidine-1-carboxylate;benzyl (3R,4S)-3-(N-(ethoxycarbonyl)-N-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)glycyl)-4-ethylpyrrolidine-1-carboxylate;benzyl(3R,4S)-3-(N-(ethoxycarbonyl)-N-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)glycyl)-4-ethylpyrrolidine-1-carboxylate
CAS No.:2050038-81-6
Molecular Formula:C32H35N5O7S
InChIKeys:ITDMYESIPHGZCQ-RSXGOPAZSA-N
Molecular Weight:633.7
Exact Mass:633.22571965
EC Number:944-343-2
Categories:
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Drug impurity reference,Impurity reference,Reference substance,impurity
-
Location:
Hengfeng Wanda (Hubei) Pharmaceutical Technology Co., LTD., Hongshan District, Wuhan City, Hubei Province, China
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
150 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2023
Company Certificates-
Brand certification certificate
-
QUALITY MANAGEMENT SYSTEM CERTIFICATE
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Upadacitinib Impurity 21-- (3R,4S)-benzyl 3-(2-chloroacetyl)-4-ethylpyrrolidine-1-carboxylate
Pharmaceutical Grade / 90%
-
-
-
-
Upadacitinib Impurity 1((3S,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate)
Pharmaceutical Grade / 90%
-